Abstract
Mycophenolic acid was firstly used in clinical practice during the mid 90s in clinical transplantation, documenting its superiority as antiproliferative agent in comparison with azathioprine. Due to its pleiotropic mechanism of action, mycophenolic acid was thought to be effective in both immune and nonimmune diseases involving the kidney. Its efficacy in lupus nephritis is well documented by both single center and multicenter randomized studies. Recent studies documented the efficacy of MMF (morpholinoethyl ester of mycophenolic acid) in some progressive idiopathic glomerulonephritis such as steroid resistant nephritic syndrome, membranous glomerulonephritis and IgA nephritis. MMF efficacy is mostly documented by the reduction of proteinuria and by the stabilization of glomerular filtration rate (GFR).
Keywords: ICAM 1, renal ischemia, Serum creatinine, cyclophosphamide, glomerulopathies
2